Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

 

Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
   
Paper Publishing WeChat
Book Publishing WeChat
(or Email:book@scirp.org)

Article citations

More>>

T. Ishikawa, Y. Watanabe, “Effect of Hydroxypropylmethylcellulose (HPMC) on Therelease Pro?les and Bioavailability of a Poorly Water-Solubledrug from Tablets Prepared Using Macrogol and HPMC,” International Journal of Pharmaceutics, Vol. 202, No. 1, 2000, pp. 173-178. doi:10.1016/S0378-5173(00)00426-9

has been cited by the following article:

  • TITLE: Development and in Vitro-in Vivo Evaluation of Controlled Release Matrix Tablets of Desvenlafaxine

    AUTHORS: Shashidhar Reddy Dodda, Prakash Rao B

    KEYWORDS: Desvenlafaxine; Pharmacokinetics; ER Matrix Tablet; In Vitro Kinetics; Depressio

    JOURNAL NAME: Pharmacology & Pharmacy, Vol.3 No.1, January 12, 2012

    ABSTRACT: The objective of this investigation was to prepare extended release tablet containing matrix granules of Desvenlafaxine succinate monohydrate and to study its in vitro release and in vivo absorption. The design of dosage form was performed by choosing hydrophilic hydroxypropyl methyl cellulose (HPMC K100M), sodium carboxyl methyl cellulose (Blanose), microcrystalline cellulose (MCC) and lactose monohydrate polymers as matrix builders and polyvinyl pyrolidine (Kollidon K30) as granulating polymers. Granules were prepared by composing drug with HPMC K100M, sodium CMC, MCC and lactose monohydrate by spray drying method. Optimized formulation of Desvenlafaxine succinate monohydrate was formed by using 20% HPMC K100M, 26.6% MCC, 6.6% of sodium CMC (Blanose), 13.3% of lactose monohydrate and 5% ratio of Kollidon K30 as binder. Tablets were compressed with free flowing optimized granules of uniform drug content. This extended the release period up to 24 h in vitro study. Similarity factor and mean dissolution time were also reported to compare various dissolution profiles. The network formed by HPMC, MCC and Blanose had been coupled satisfactorily with the controlled resistance. Biopharmaceutical study of this optimized dosage form in rabbit model showed 24 h prolonged drug release in vivo. A close correlation (R2 = 0.9833) was established between the in vitro release and the in vivo absorption of drug. The results suggested that wet granulation with spray dried technique, is a suitable method to formulate sustained release Desvenlafaxine succinate monohydrate and it can Perform therapeutically better than conventional immediate release dosage form.